#United States #Durham #Clinical Trials #hyperCORE International #Atlas Clinical Research

hyperCORE International Welcomes Atlas Clinical Research

hyperCORE International has recently announced an exciting addition to its partner site network. Atlas Clinical Research, headquartered in Durham, North Carolina, is now part of hyperCORE's expansive network, which aims to bolster the scale and efficiency of clinical trials across North America. This collaboration is not just about expansion; it epitomizes a strategic move towards enhancing patient access to cutting-edge treatments and advancing the field of clinical research.

About Atlas Clinical Research

Atlas Clinical Research stands out as a therapeutically-focused clinical research site network. They excel in utilizing centralized process excellence and integrated technology to foster connections between patients and innovative treatments. With specialized expertise in various therapeutic areas such as infectious diseases, central nervous system disorders, gastroenterology, cardiovascular health, and metabolic disorders, Atlas aims to broaden its footprint throughout the United States.

The organization is dedicated to partnering with biopharmaceutical sponsors and Contract Research Organizations (CROs) to ensure that clinical trials progress efficiently and effectively. Their relentless focus on speed, data quality, and patient care positions them as an ideal partner within hyperCORE's network of clinical research organizations.

Enhancing Clinical Trial Capabilities

The integration of Atlas Clinical Research into the hyperCORE network amplifies the organization's capability to conduct clinical trials swiftly while ensuring high-quality data collection and patient care. As Rajat Mayur, Chief Commercial Officer of Atlas, articulated, this partnership gives them the opportunity to align with a network of notable research organizations while simultaneously enhancing the value offered to sponsors and patients.

Atlas's operational model revolves around accelerating clinical trial timelines and increasing patient enrollment, which could significantly benefit ongoing and future studies under the hyperCORE umbrella. Carlos Orantes, President of hyperCORE, expressed his enthusiasm, noting that the addition of Atlas strengthens hyperCORE's offering by providing centralized access to over 150 high-performing research sites. This collective capability is particularly advantageous for sponsors looking for reliable and high-performing sites across various regions.

hyperCORE's Commitment to Clinical Research Excellence

hyperCORE International is recognized as an industry leader in clinical trials, characterized by a robust network of award-winning research facilities that span multiple continents and cover a wide array of therapeutic areas. Currently comprised of over 125 active research sites in five countries, the organization prides itself on its outstanding track record of completing more than 7,000 studies with upwards of 150,000 randomized participants.

The operational synergy between hyperCORE and its partners leads to streamlined clinical and business processes, facilitating best practice sharing across the network. This commitment to achieving excellence extends to ensuring subject safety, data integrity, rapid study startup, competitive patient enrollment rates, and exceptional retention—all vital components in the clinical trials landscape.

Looking Ahead

With Atlas Clinical Research now part of the hyperCORE network, both entities are poised to significantly impact the clinical research domain. By enhancing patient access to trials and ensuring high-quality execution, they are not only working to bring new treatments to market faster but also striving to improve the overall healthcare landscape.

In conclusion, the collaboration between hyperCORE International and Atlas Clinical Research represents a forward-thinking approach to clinical research partnerships. As the healthcare landscape continually evolves, such strategic alliances will be crucial in propelling the field of clinical trials towards greater efficiency and effectiveness, ultimately benefiting patients seeking novel therapeutic options.